Biotechnology

BioAccelergy Ventures has signed a joint-development agreement with ExxonMobil Research and Engineering Company (ExxonMobil) to progress development of a new bio-base stock for lubricants manufacturing from seed and vegetable oil. The multi-year agreement aims to demonstrate the feasibility of producing bio-base stocks at a cost-effective commercial scale to reduce greenhouse gas emissions. BioAccelergy will provide its … Read more

Aalto Bio Reagents ltd., a leading developer of critical raw materials and reagents for the development of diagnostic tests globally, announced today that its SARS-CoV-2 n proteins CK6404 and monoclonals CA1360 that are part of numerous rapid assays that are being run in Europe and the U.S. on the screening frontline for detection of COVID-19 … Read more

Gb Sciences, a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine release syndrome (CRS), one of the most dangerous complications of COVID-19. With reports of the arrival of the Omicron variant of the coronavirus in multiple countries, the Gb Sciences team plans to move … Read more

Florida Biotech has selected Tampa for its North American headquarters, research and development, and brand operations, citing the region’s strong talent pool, research universities, strong logistics and growing reputation as a center for biotech and life sciences. Florida Biotech is a sustainable wellness innovation company, developing solutions for industry and home focusing on natural compounds … Read more

Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company Gb Sciences has taken innovative steps to speed up the process and is developing key relationships to further advance the clinical development of its novel, plant-inspired therapies for the prescription drug market. To expedite … Read more

Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, will present its lead development candidate, AR-67, at this year’s 5th Meridian Clinical Trials (MCT) conference, Nov. 22-23, 2021, via their online platform.  The presentation, “VIVACITAS ONCOLOGY PRESENTS OUR LEAD COMPOUND, AR-67, A NOVEL 3RD GENERATION CAMPTOTHECIN IN RECURRENT GLIOBLASTOMA,” details AR-67 (Topoisomerase I Inhibitor) as a highly … Read more

Vivacitas Oncology, a privately-held oncology company focused on tough-to-treat cancers, and Image Analysis Group (IAG), a premier image-analysis company and developer of the proprietary Artificial Intelligence (AI)-assisted Dynamika™ platform, will present a poster at this year’s annual Society of Neuro-Oncology (SNO) conference November 18-21, 2021, in Boston, MA.  The poster “RESPONSE EVALUATION OF AR-67 FROM … Read more